Diabetic Kidney Disease

被引：163

作者：

Bonner, Ryan ^{[1
,2
]}

Albajrami, Oltjon ^{[1
,2
]}

Hudspeth, James ^{[1
,2
]}

Upadhyay, Ashish ^{[1
,2
]}

机构：

[1] Boston Med Ctr, Dept Med, Sect Nephrol, 800 Harrison Ave,G009, Boston, MA 02118 USA

[2] Boston Univ, Sch Med, 800 Harrison Ave,G009, Boston, MA 02118 USA

来源：

PRIMARY CARE | 2020年 / 47卷 / 04期

关键词：

Diabetic kidney disease; Diabetic nephropathy; Chronic kidney disease; Albuminuria; RENIN-ANGIOTENSIN SYSTEM; CARDIOVASCULAR OUTCOMES; ACE-INHIBITION; DOUBLE-BLIND; THERAPEUTIC TARGET; GLUCOSE CONTROL; RENAL OUTCOMES; DUAL BLOCKADE; TYPE-2; NEPHROPATHY;

D O I：

10.1016/j.pop.2020.08.004

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease in the United States. Approximately 30% to 40% of individuals with diabetes mellitus develop DKD, and the presence of DKD significantly elevates the risk for morbidity and mortality. Understanding of DKD has grown in recent years. This review describes the pathogenesis of DKD and expands on evidence-based strategies for DKD management, integrating traditional approaches for hyperglycemia, hypertension, and albuminuria management with emerging therapeutic options. Given the public health burden of DKD, it is essential to prioritize prevention, recognition, and management of DKD in the primary care setting.

引用

页码：645 / 659

页数：15

共 69 条

[1] Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].

Adler, AI ;

Stevens, RJ ;

Manley, SE ;

Bilous, RW ;

Cull, CA ;

Holman, RR .

KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232

[2] Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019 [J].

Cefalu, William T. ;

Berg, Erika Gebel ;

Saraco, Mindy ;

Petersen, Matthew P. ;

Uelmen, Sacha ;

Robinson, Shamera .

DIABETES CARE, 2019, 42 :S124-S138

[3]

American Diabetes Association, 2019, Clin. Diabetes, V37, P11

[4]

[Anonymous], 2018, FDA DRUG SAF COMM FD

[5]

Arnett DK, 2019, CIRCULATION, V140, pE563, DOI [10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.009, 10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.010]

[6] Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors [J].